Supporting Information

Table of Contents

S1. ICP-AES analysis

S2. EDS analysis

S3. BET analysis

S4. Melting Point of Synthesized Compounds

S5. Spectral data of the compounds

S6. FT-IR, ¹H and ¹³C NMR spectra of the compounds.

S1. ICP-AES analysis.

Observed data (PPM):

Element	PPM	Atomic ratio
Р	65.274	1.05
Мо	1276.227	6.68
W	1907.004	5.18

S2. EDS analysis



Figure 1. EDS images of (a) bulk PMo₇W₅ (b) 20% PMo₇W₅/Kaolin.

S3. BET analysis

(a) Bulk PMo₇W₅





Pore Width (Å)

(b) Pure Karolin clay

J

ven iv.



Multi-Point BET Plot

Surface Area =

14.382 m³/g

BJH method Desorption dV(d)



(c) 20% PMo₇W₅/Kaolin.

4

Cell ID:

Multi-Point BET Plot



BJH method Desorption dV(d)

-



S4. Melting Point of Synthesized Compound

Table 1. Melting point of ethyl 6-methyl-2-oxo-4-aryl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (4a-n)

сно	<mark>ໍ່ມີ</mark> + ມີ	20% PM0 ₇ W	V ₅ /Kaolin
(1)	$\begin{array}{c} \bullet \bullet$	Solvent-free	$e, 80 \circ C$ HN OEt
Entry	Aldehydes	Product	(4a-n) Melting points ^c (°C) ^{Ref}
	C_6H_5		201-203/201-203 ^{1,2}
4b	<i>p</i> -ClC ₆ H ₄		210-212/212-215 ^{3,4}
4c	<i>m</i> -BrC ₆ H ₄	O H H H O Et	185-187/183-185 ⁵
4d	<i>p</i> -NO ₂ C ₆ H ₄	$ \begin{array}{c} O^{*} & N \\ H \\ NO_{2} \\ HN \\ OEt \\ OEt OEt $	198-200/208-209 ⁶
4e	p-FC ₆ H ₄		178-180/180-183 ^{1,5}
4f	<i>p</i> -OMeC ₆ H ₄	H OMe HN O HN H	200-201/201-203 ³



^{*a*}Reaction conditions: Aldehydes (1a-n) (3 mmol), ethyl acetoacetate (3 mmol), and urea (3.2 mmol) in 20% PMo₇W₅/Kaolin (0.1g) stirred at 80 °C; ^{*b*} isolated yields, ^{*c*} melting points are in good contact with those reported in the literature.

S5. Spectral data of the compounds

4a. ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate



IR (ATR, υ cm⁻¹): 694, 761, 1085, 1215, 1298, 1378, 1459, 1638, 1701, 2929, 2969, 3107, 3230. ¹H NMR (400 MHz, DMSO-δ6) δppm= 1.08 (t, J=7.1 Hz, 3 H), 2.24 (s, 3 H), 3.97 (q, J=7.0 Hz, 2 H), 5.14 (d, J=2.8 Hz, 1 H), 7.19 - 7.27 (m, 3 H), 7.28 - 7.35 (m, 2 H), 7.73 (br. s., 1 H), 9.18 (s, 1 H). ¹³C NMR (100 MHz, DMSO-δ6) δppm= 13.7 (s), 17.4 (s), 53.6 (s), 58.8 (s), 98.9 (s), 125.9 (s), 126.9 (s), 128.0 (s), 144.5 (s), 148.0 (s), 151.8 (s), 165.0 (s).

4b. ethyl 6-methyl-4-(4-Chlorophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5carboxylate



IR (ATR, υ cm⁻¹): 676, 775, 1010, 1085, 1217, 1285, 1419, 1456, 1640, 1707, 2964, 3110, 3235, 3332. ¹H NMR (CDCl₃, 400MHz): 1.17(t, J = 7.1 Hz, 3H), 2.33 (s, 3H), 4.07 (q, 2H), 5.37 (d, J = 2.6 Hz, 1H), 5.96 (br. s., 1H), 7.21-7.31 (m, 4H), 8.19 (s, 1H). ¹³C NMR (CDCl₃, 100 MHz): 14.1 (s), 18.7 (s), 55.1 (s), 60.1 (s), 101.1 (s), 128.0 (s), 128.9 (s), 133.7 (s), 142.2 (s), 146.5 (s), 153.3 (s), 165.4 (s).

4d. ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate



IR (ATR, υ cm⁻¹): 690, 775, 857, 1087, 1211, 1297, 1347, 1385, 1460, 1517, 1638, 1701, 2979, 3110, 3230. ¹H NMR (400 MHz, DMSO-δ6) δppm= 1.09 (t, J=7.1 Hz, 3 H), 2.26 (s, 3 H), 3.98

(q, J=7.1 Hz, 2 H), 5.27 (d, J=3.4 Hz, 1 H), 7.46 - 7.56 (m, 2 H), 7.85 - 7.96 (m, 1 H), 8.18 - 8.30 (m, 2 H), 9.32 - 9.42 (m, 1 H). ¹³C NMR (100 MHz, DMSO-δ6) δppm= 13.6 (s), 17.5 (s), 53.3 (s), 59.0 (s), 97.7 (s), 123.4 (s), 127.2 (s), 146.3 (s), 149.0 (s), 151.3 (s), 151.6 (s), 164.6 (s).

4e. ethyl 4-(4-fluorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate



IR (ATR, υ cm⁻¹): 945, 1083, 1157, 1215, 1283, 1451, 1602, 3220, 3349⁻¹H NMR (400 MHz, DMSO- δ6) δppm= 1.08 (t, J=7.1 Hz, 3 H), 2.25 (s, 3 H), 3.97 (q, J=6.8 Hz, 2 H), 5.15 (d, J=2.5 Hz, 1 H), 7.14 (t, J=8.8 Hz, 2 H), 7.26 (dd, J=8.4, 5.6 Hz, 2 H), 7.78 (br. s., 1 H), 9.28 (br. s., 1 H). ¹³C NMR (100 MHz, DMSO- δ6) δppm =13.9 (s), 17.6 (s), 53.2 (s), 59.1 (s), 99.0 (s), 114.9 (s), 115.1 (s), 128.1 (s), 128.1 (s), 140.9 (s), 141.0 (s), 148.4 (s), 151.9 (s), 159.6 (s), 160.0 (s), 162.4 (s), 165.1 (s)

4l. ethyl 4-(4-bromophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate



IR (ATR, υ cm⁻¹): 662, 763, 851, 1014, 1079, 1161, 1213, 1283, 1381, 1450, 1630, 2981, 3214, 3342. ¹H NMR (400 MHz, DMSO- δ6) δppm = 1.09 (t, J=7.1 Hz, 3 H), 2.25 (s, 3 H), 3.98 (q, J=7.1 Hz, 2 H), 5.13 (d, J=3.1 Hz, 1 H), 7.19 (m, J=8.4 Hz, 2 H), 7.48 - 7.57 (m, 2 H), 7.78 (br. s., 1 H), 9.27 (s, 1 H). ¹³C NMR (100 MHz, DMSO- δ6) δppm =13.9 (s), 17.6 (s), 53.3 (s), 59.1 (s), 98.6 (s), 120.1 (s), 128.4 (s), 131.1 (s), 144.0 (s), 148.5 (s), 151.8 (s), 159.5 (s), 165.0 (s)



4a. ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate



4b. ethyl 6-methyl-4-(4-Chlorophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5carboxylate







4d. ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate



4e. ethyl 4-(4-fluorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylat





4l. ethyl 4-(4-bromophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate







References

- J. Safaei Ghomi, R. Teymuri and A. Ziarati, *Monatsh Chem*, 2013, **144**, 1865–1870.
- 2 R. J. Kalbasi, A. R. Massah and B. Daneshvarnejad, *Appl. Clay Sci.*, 2012, 55, 1–9.
- 3 Q. Wang and W. Pei, J. Iran. Chem. Soc, 2010, 7, 318–321.
- M. M. Heravi, F. Derikvand and F. F. Bamoharram, *J. Mol. Catal. A Chem.*, 2005, 242, 173–175.
- 5 Y. Zhang, B. Wang, X. Zhang, J. Huang and C. Liu, *Molecules*, 2015, **20**, 3811–3820.
- J. Mondal, T. Sen and A. Bhaumik, *Dalton Trans.*, 2012, **41**, 6173.